The Effect of Letrozole on Symptomatic Uterine Leiomyoma
Not Applicable
- Conditions
- Symptomatic Uterine Leiomyoma.Leiomyoma of uterus
- Registration Number
- IRCT201402161760N32
- Lead Sponsor
- Vice Chancellor for Research of Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Premenopausal women aged 42-18 years with a single Intramural leiomyoma size> 5 cm; Women with uterine myoma> 5cm with other myoma size <2cm
Exclusion criteria:
Other women with myoma size> 2cm; Women with uterine leiomyomas treated with estrogen or progesterone last month; Women with a history of major medical problems or previous medical or surgical treatment for leiomyomas; All women with leiomyoma sizes 2 to 5cm
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eiomyoma tumors. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Ultrasound.;Uterine volume. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: ?????????.
- Secondary Outcome Measures
Name Time Method Serum gonadotropin. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Laboratory.;Serum Estradiol. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: Laboratory.;Menstrual pattern. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: clinical.;Clinical symptoms associated with leiomyoma. Timepoint: On admission and on days 30 and 90 after treatment. Method of measurement: clinical.